Sodium-glucose cotransporter-2 inhibitors (SGLT2i), widely used in the management of diabetes mellitus (DM), chronic kidney disease (CKD), and congestive heart failure (CHF), promote urinary glucose excretion, potentially fostering an environment favorable to bacterial and fungal growth. Here, SLC5A2 is linked to chronic kidney disease.